Qi Wenwei, Zhang Nixiao, Korantzopoulos Panagiotis, Letsas Konstantinos P, Cheng Min, Di Fusheng, Tse Gary, Liu Tong, Li Guangping
Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
School of Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
PLoS One. 2017 Mar 7;12(3):e0170955. doi: 10.1371/journal.pone.0170955. eCollection 2017.
Glycated hemoglobin (HbA1c) is a long-term measure of glucose control. Although recent studies demonstrated a potential association between HbA1c levels and the risk of atrial fibrillation (AF), the results have been inconsistent. The aim of this meta-analysis is to evaluate the utility of HbA1c level in predicting AF.
PubMed and the Cochrane Library databases were searched for relevant studies up to March 2016. Prospective cohort studies and retrospective case-control studies were included. Relative risk (RR) or odds ratio (OR) with 95% confidence intervals (CIs) of AF development were determined for different HbA1c levels. The random effect model was conducted according to the test of heterogeneity among studies. Subgroup analyses and meta-regression models were carried out to identify potential sources of heterogeneity.
Eight prospective cohort studies with 102,006 participants and 6 retrospective case-control studies with 57,669 patients were finally included in the meta-analysis. In the primary meta-analysis, HbA1c levels were not associated with an increased risk of AF whether as a continuous (RR, 1.06; 95% CI, 0.96-1.18) or categorical variable (RR, 0.99; 95% CI, 0.83-1.18). Nevertheless, prospective studies showed about 10% increased risk of AF with elevated HbA1c levels both as a continuous (RR, 1.11; 95% CI, 1.06-1.16) and as a categorical variable (RR, 1.09; 95% CI, 1.00-1.18). In subgroup analyses, pooled results from studies with longer follow-up durations, published after 2012, aged < 63 years, with exclusion of cardiac surgery patients demonstrated an increased risk of AF for every 1% increase in HbA1c levels, while studies conducted in the United States with longer follow-up (more than 96 months), larger sample size and higher quality score (≥6) showed an increased risk of AF for higher HbA1c level as a categorical variable.
Elevated serum HbA1c levels may be associated with an increased risk of AF, but further data are needed. Serum HbA1c levels might be considered as a potential biomarker for prediction of AF.
糖化血红蛋白(HbA1c)是血糖控制的一项长期指标。尽管近期研究表明HbA1c水平与房颤(AF)风险之间可能存在关联,但结果并不一致。本荟萃分析的目的是评估HbA1c水平在预测房颤方面的效用。
检索PubMed和Cochrane图书馆数据库,查找截至2016年3月的相关研究。纳入前瞻性队列研究和回顾性病例对照研究。确定不同HbA1c水平下房颤发生的相对风险(RR)或比值比(OR)及95%置信区间(CI)。根据研究间异质性检验采用随机效应模型。进行亚组分析和荟萃回归模型以识别异质性的潜在来源。
最终,8项有102,006名参与者的前瞻性队列研究和6项有57,669名患者的回顾性病例对照研究纳入了荟萃分析。在主要的荟萃分析中,无论HbA1c水平作为连续变量(RR,1.06;95%CI,0.96 - 1.18)还是分类变量(RR,0.99;95%CI,0.83 - 1.18),均与房颤风险增加无关。然而,前瞻性研究显示,HbA1c水平升高时,无论作为连续变量(RR,1.11;95%CI,1.06 - 1.16)还是分类变量(RR,1.09;95%CI,1.00 - 1.18),房颤风险均增加约10%。在亚组分析中,随访时间较长、2012年后发表、年龄<63岁且排除心脏手术患者的研究汇总结果显示,HbA1c水平每升高1%,房颤风险增加;而在美国进行的随访时间较长(超过96个月)、样本量较大且质量评分较高(≥6)的研究显示,较高的HbA1c水平作为分类变量时,房颤风险增加(RR,1.09;95%CI,1.00 - 1.18)。
血清HbA1c水平升高可能与房颤风险增加有关,但还需要更多数据。血清HbA1c水平可被视为预测房颤的潜在生物标志物。